Phase 3 Epilepsy Trial, Recruiting NCT05431595 Sponsor: M.D. Anderson Cancer Center Condition: Epilepsy
Back to Epilepsy

Phase 3 Epilepsy Trial, Recruiting

NCT05431595
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with advanced cancer that has spread, cannot be cured, or has come back
  • You are currently being seen by a palliative care team while in the hospital
  • You have been diagnosed with delirium (a state of sudden confusion) according to standard medical guidelines
  • You are experiencing an active or mixed form of delirium with restlessness or agitation, and have already been given medication or other measures (such as a sitter or physical restraints) to manage it
  • You are 18 years of age or older
  • Your main medical team has given permission for you to take part in the study
  • Family caregivers may also join if they are a spouse, adult child, sibling, parent, other relative, or a partner identified by the patient
  • Family caregivers must be 18 years of age or older

Who may not be able to join:

  • You are already taking high regular doses of certain medications: haloperidol (more than 4 mg/day), chlorpromazine (more than 100 mg/day), or valproate (more than 750 mg/day)
  • You have a history of myasthenia gravis, acute narrow-angle glaucoma, or confusion caused by liver failure
  • You have significant liver problems shown in recent blood tests within the past month (confirm with trial site)
  • You have a history of a serious reaction to antipsychotic medications called neuroleptic malignant syndrome
  • You have had seizures within the past month
  • You have a history of Parkinson's disease or dementia
  • A recent heart test (ECG) within the past month showed a specific abnormality in your heart rhythm (QTc interval over 500 ms)
  • You have had a known allergic reaction to haloperidol, chlorpromazine, or valproate
  • You have had a pancreas inflammation (pancreatitis) within the past month
  • You are currently taking lamotrigine, phenobarbital, or carbamazepine
  • You are showing physical signs that death is very close (confirm with trial site)
  • You are pregnant
  • You currently have an active COVID-19 infection

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: David Hui, MD, M.D. Anderson Cancer Center

Phone: (713) 792-6258

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
19 July 2022
Est. completion
2 February 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Edmonton Symptom Assessment Scale Questionnaire

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov